In addition, CCL20 markedly increased cell migration and invasion and the activities of related proteases in basal-like/triple-negative breast cancer cell lines but not in luminal breast cancer cell lines, suggesting that the targeting of CCL20 may be more effective in patients with aggressive breast cancer. Here, CCL20 is linked to breast cancer.